Related Experiment Video

Updated: May 30, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Hot-topic debate on hepatitis C virus: the type of immunosuppression matters

James F Trotter1

  • 1Baylor University Medical Center, Dallas, TX 75246, USA. james.trotter@baylorhealth.edu

Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
|August 19, 2011
PubMed

Insights

Hepatitis C virus (HCV) recurrence after liver transplant is linked to rejection treatment. Cyclosporine may improve sustained virological response, while avoiding agents causing insulin resistance could slow disease progression.

Area of Science:

  • Hepatology
  • Immunosuppression
  • Virology

Background:

  • Hepatitis C virus (HCV) recurrence remains a significant challenge post-liver transplantation.
  • Understanding the impact of immunosuppressive regimens on HCV recurrence is critical for patient outcomes.

Purpose of the Study:

  • To evaluate the association between rejection treatment and HCV recurrence after liver transplantation.
  • To assess the effects of specific immunosuppressive agents on HCV recurrence and disease progression.

Main Methods:

  • Analysis of patient data focusing on immunosuppressive strategies and HCV recurrence rates.
  • Evaluation of sustained virological response (SVR) in relation to specific immunosuppressants.
  • Investigation of the role of metabolic factors like insulin resistance in post-transplant fibrosis.

Main Results:

  • Treatment of rejection is a key factor influencing severe HCV recurrence.
  • The impact of calcineurin inhibitors, corticosteroids, and mycophenolate mofetil on HCV recurrence is currently unclear.
  • Cyclosporine demonstrated an association with higher SVR rates in HCV patients.
  • Insulin resistance and diabetes correlate with fibrosis progression in HCV-infected liver recipients.

Conclusions:

  • Optimizing rejection management is crucial to mitigate severe HCV recurrence post-liver transplant.
  • Further research is needed to clarify the role of common immunosuppressants in HCV recurrence.
  • Cyclosporine may offer a virological benefit for HCV patients.
  • Immunosuppressive agents that do not induce insulin resistance may help slow disease progression in HCV liver transplant recipients.
Abstract

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...